ZA939577B - Treatment of inflammatory bowel disease with IFN-gamma inhibitors - Google Patents

Treatment of inflammatory bowel disease with IFN-gamma inhibitors

Info

Publication number
ZA939577B
ZA939577B ZA939577A ZA939577A ZA939577B ZA 939577 B ZA939577 B ZA 939577B ZA 939577 A ZA939577 A ZA 939577A ZA 939577 A ZA939577 A ZA 939577A ZA 939577 B ZA939577 B ZA 939577B
Authority
ZA
South Africa
Prior art keywords
treatment
inflammatory bowel
bowel disease
ifn
gamma inhibitors
Prior art date
Application number
ZA939577A
Other languages
English (en)
Inventor
Avi J Ashkenazi
Rebecca H R Ward
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA939577B publication Critical patent/ZA939577B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA939577A 1992-12-29 1993-12-21 Treatment of inflammatory bowel disease with IFN-gamma inhibitors ZA939577B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99783592A 1992-12-29 1992-12-29

Publications (1)

Publication Number Publication Date
ZA939577B true ZA939577B (en) 1995-06-21

Family

ID=25544454

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA939577A ZA939577B (en) 1992-12-29 1993-12-21 Treatment of inflammatory bowel disease with IFN-gamma inhibitors

Country Status (12)

Country Link
US (5) US6558661B1 (ja)
EP (1) EP0695189B1 (ja)
JP (1) JP3887011B2 (ja)
AT (1) ATE173630T1 (ja)
AU (1) AU678429B2 (ja)
CA (1) CA2148907C (ja)
DE (1) DE69322289T2 (ja)
DK (1) DK0695189T3 (ja)
ES (1) ES2126094T3 (ja)
IL (2) IL108007A (ja)
WO (1) WO1994014467A1 (ja)
ZA (1) ZA939577B (ja)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
WO1997037679A1 (en) * 1996-04-10 1997-10-16 Board Of Trustees Of The University Of Illinois Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
EP1137766B1 (en) 1998-12-09 2005-09-28 Protein Design Labs, Inc. Use of il-12 antibodies to treat psoriasis
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
GB0009503D0 (en) * 2000-04-17 2000-06-07 Univ Liverpool Screening method for compounds
DK1290027T3 (da) 2000-04-28 2010-01-18 Planet Biotechnology Inc Immunoadhæsin til forebyggelse af rhinovirusinfektion
EP1485476A2 (en) * 2002-03-12 2004-12-15 Novo Nordisk A/S Dimeric tf antagonist
AU2003249641B2 (en) 2002-05-16 2009-08-20 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
JP2005529152A (ja) * 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
US20040096396A1 (en) * 2002-07-03 2004-05-20 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20060104946A1 (en) * 2002-08-23 2006-05-18 Zymogenetics, Inc. Method for treating inflammatory bowel disease
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
JP3738268B2 (ja) * 2003-02-24 2006-01-25 森永乳業株式会社 インターロイキン−６産生抑制剤
NZ542866A (en) * 2003-04-23 2009-07-31 Medarex Inc Compositions and methods for the therapy of inflammatory bowel disease
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
GB0323793D0 (en) * 2003-10-10 2003-11-12 Imp College Innovations Ltd Methods
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
US7361644B2 (en) * 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US20050260155A1 (en) * 2004-05-18 2005-11-24 Gopala Kovvali Compositions and methods for treatment of ulcerative colitis
CN102863532A (zh) 2004-06-21 2013-01-09 米德列斯公司 干扰素α受体1抗体及其用途
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
MX2007008719A (es) 2005-01-27 2007-09-11 Novimmune Sa Anticuerpos anti-interferon gamma y metodos de uso de los mismos.
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
ATE528311T1 (de) * 2005-08-09 2011-10-15 Glycomimetics Inc Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
JP5209476B2 (ja) 2005-09-02 2013-06-12 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP2074132B1 (en) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
CA2677747A1 (en) * 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN102088983B (zh) * 2008-06-13 2013-01-30 糖模拟物有限公司 利用选择的糖模拟化合物的血液癌症的治疗
CN102203258A (zh) * 2008-07-02 2011-09-28 新兴产品开发西雅图有限公司 TGF-β拮抗剂多靶点结合蛋白
CA2729749A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tnf-a antagonist multi-target binding proteins
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
EP2791168A1 (en) 2011-11-23 2014-10-22 Amgen Inc. Methods of treatment using an antibody against interferon gamma
AU2012358150B2 (en) 2011-12-22 2017-07-20 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
CA2904722C (en) 2013-03-15 2023-01-03 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
CA2968391C (en) 2014-12-03 2022-04-26 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US20180051078A1 (en) * 2015-03-16 2018-02-22 Cedars-Sinai Medical Center Methods of treating inflammatory bowel disease with ifn-gamma therapy
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
MX2017014294A (es) 2015-05-07 2018-08-09 Novimmune Sa Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
US10266745B2 (en) * 2017-02-03 2019-04-23 Saudi Arabian Oil Company Anti-bit balling drilling fluids, and methods of making and use thereof
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
GB8519848D0 (en) 1985-08-07 1985-09-11 Schweiz Rotes Kreuz Treatment of chronic inflammatory disease
IL78444A (en) 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
IL88378A (en) 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU625866B2 (en) * 1989-04-19 1992-07-16 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
US5061786A (en) 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
CA2081309A1 (en) 1990-04-24 1991-10-25 Paul J. Zavodny Soluble, truncated gamma-interferon receptors
DE69115917T2 (de) 1990-09-27 1996-05-23 Schering Corp Humane gammainterferonantagonisten
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
CA2114168A1 (en) 1993-03-05 1994-09-06 Zlatko Dembic Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
JPH0746628A (ja) * 1993-06-29 1995-02-14 Toshiba Corp 画像信号符号化装置及び画像信号復号化装置
AU764211C (en) * 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
JP2005529152A (ja) 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Also Published As

Publication number Publication date
IL124478A0 (en) 1998-12-06
DK0695189T3 (da) 1999-08-09
EP0695189A1 (en) 1996-02-07
EP0695189B1 (en) 1998-11-25
US20030012790A1 (en) 2003-01-16
CA2148907C (en) 2008-07-08
US6558661B1 (en) 2003-05-06
JPH08504817A (ja) 1996-05-28
DE69322289T2 (de) 1999-05-20
JP3887011B2 (ja) 2007-02-28
ES2126094T3 (es) 1999-03-16
AU678429B2 (en) 1997-05-29
CA2148907A1 (en) 1994-07-07
US20070020268A1 (en) 2007-01-25
US20030012787A1 (en) 2003-01-16
US7300656B2 (en) 2007-11-27
WO1994014467A1 (en) 1994-07-07
US20070104712A1 (en) 2007-05-10
IL108007A (en) 2005-08-31
US7449176B2 (en) 2008-11-11
ATE173630T1 (de) 1998-12-15
AU5898894A (en) 1994-07-19
DE69322289D1 (de) 1999-01-07
IL108007A0 (en) 1994-04-12

Similar Documents

Publication Publication Date Title
ZA939577B (en) Treatment of inflammatory bowel disease with IFN-gamma inhibitors
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
BG101841A (en) Cellular adhesion inhibitors
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
ZA943744B (en) Therapeutic substituted guanidines
NO996578L (no) Urokinase-inhibitorer
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
EP0876387A4 (en) PROCESS FOR IMPROVING THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
IL104716A0 (en) Aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ace
FI941826A (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
ZA926837B (en) A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist
IL110365A0 (en) 2-Amino-4-phenyl-4-oxo-butyric acid derivatives, their preparation and pharmaceutical compositions containing them
SE9201249L (sv) Antikonception vid primater av honkoen utan paaverkan av den menstruella cykeln
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
MD2196B2 (ro) Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
SE9603725D0 (sv) New teatment
AP2002002446A0 (en) Method for administering a phosphodiesterase 4 inhibitor.
ITRM920222A0 (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
PL308201A1 (en) Applicationj of hialuronic acid and various forms thereof in preventing recurrent arteriostenosis
NO962503L (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose